Web1 day ago · In 2024, Abbott Laboratories acquired Cephea Valve Technologies, a medical device company developing a catheter-based system for the treatment of mitral valve disease. WebJot Dx ICM is supported by SyncUP, a personalized service that delivers one-on-one training and education to help patients connect and stay connected to their ICM. In September 2024, Abbott announced that it has planned to acquire Cephea Valve Technologies, Inc. The acquisition is likely to strengthen Abbott’s structural heart portfolio.

Abbott To Acquire Cephea Valve Technologies – PharmaLive

The patient treated was an 83-year-old woman with history of nonischemic congestive heart failure (class III New York Heart Association), atrial fibrillation, and moderate chronic kidney disease (glomerular filtration rate =42 mL/min). The patient was referred to the Heart Valve Clinic at Lille University … See more Cardiac computed tomography analysis was performed using a dedicated planning analytical software (3-mensio version 9.1; Pie Medical Imaging, … See more The device used in this procedure is one of the few using the transseptal approach to deliver and anchor a trileaflet pericardial valve. The valve design consists of a unique architecture including a ventricular disk, a central leaflet … See more The patient was transferred to the Intensive Care Unit and extubated 4-hours later without any complications. At 24-hours, transthoracic echocardiography imaging remained unchanged with total resolution of the mild … See more The interventional procedure was performed under general anesthesia and transesophageal echocardiographic guidance. Femoral vein access was performed using … See more WebMay 10, 2024 · Mitral regurgitation (MR) is the most prevalent form of valvular heart disease in the developed world, affecting about 10% of people aged over 75 years. 1–3 MR can … rochester red wings suites

Cephea Valve Technologies, Inc.: Private Company Information - Bl…

WebThe Tendyne transcatheter mitral valve replacement system for the treatment of mitral regurgitation Authors Jayendrakumar S Patel 1 , Samir R Kapadia 1 Affiliation 1 Heart & Vascular Institute, Cleveland Clinic, 9500 Euclid Ave, Cleveland, OH 44195, USA. PMID: 30920301 DOI: 10.2217/fca-2024-0090 Abstract WebJan 16, 2024 · Financial terms were not disclosed. Abbott provided capital and secured an option to purchase Cephea in 2015. Cephea's technology is being developed to provide … WebJan 16, 2024 · ABBOTT PARK, Ill., Jan. 16, 2024 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today that it has exercised its option to purchase Cephea Valve … rochester referee unit